




European  
Helicobacter &  
Microbiota  
Study  
Group

# XXXIII<sup>rd</sup> International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

September 12, 2020 | VIRTUAL CONFERENCE



## Final Programme

[www.ehmsg.org](http://www.ehmsg.org)





# XXXIII<sup>rd</sup> International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

September 12, 2020 | VIRTUAL CONFERENCE

a member of

UNITED EUROPEAN  
GASTROENTEROLOGY

**ueg**



Awardees of the Marshall and Warren Medal . . . . .	4
Welcoming Address . . . . .	5
Committees – Organisation . . . . .	6
Workshops of the EHMSG . . . . .	6
Save the Date for EHMSG 2021 . . . . .	7
Live Programme Saturday, September 12 . . . . .	8
On-Demand Talks . . . . .	11
Poster Presentations . . . . .	12
Scientific Information . . . . .	25
EHMSG Journal . . . . .	26
Acknowledgements . . . . .	27
General Information . . . . .	28
Adverts . . . . .	30 - 32

## AWARDEES OF THE MARSHALL AND WARREN MEDAL

- 2020 Hazel Mitchell, Sydney, Australia**
- 2019 Guillermo Perez-Perez, New York, NY, United States
- 2018 Kenneth McColl, Glasgow, United Kingdom
- 2017 Jean-Charles Delchier, France
- 2016 Ken Sugano, Shimotsuke, Japan
- 2015 Heidi-Ingrid Maarros, Tartu, Estonia
- 2014 Manfred Kist, Freiburg, Germany
- 2013 Masahiro Asaka, Sapporo, Japan
- 2012 Richard Hunt, Hamilton, ON, Canada
- 2011 Samy Cadranel, Brussels, Belgium
- 2010 Reinhold W. Stockbrügger, Maastricht, The Netherlands
- 2009 Pelayo Correa, Nashville, TN, United States
- 2008 Timo Kosunen, Helsinki, Finland
- 2007 Mike Dixon, Leeds, United Kingdom
- 2006 Barry Marshall, Perth, Australia & Stanislaw Konturek, Cracow, Poland

## NEXT EHMSG WORKSHOP

**September 16 - 18, 2021**  
**Belgrade, Serbia**

## Welcoming address by the President of the European Helicobacter and Microbiota Study Group Prof. Dr. Georgina Hold



Dear Colleagues, Dear Friends,

It is my great pleasure, on behalf of the European Helicobacter and Microbiota Study group (EHMSG) to welcome you to our 2020 VIRTUAL conference. Just as EHMSG has evolved over the years as a dynamic and forward-thinking society, this year we have also had to be innovative and creative in terms of delivering our annual conference, in light of the current global pandemic.

We are delighted to welcome you to a fantastic programme of world-class speakers covering many aspects of Helicobacter and microbiota current research. In addition to the one-day speaker programme, there are e-posters to view and also a number of pre-recorded talks which are available on-demand.

I can't finish this welcome address without thanking the EHMSG group and the team at the Vienna Medical Academy who together have worked tirelessly to make this virtual conference a reality. I am also hugely grateful to our sponsors who have continued to support us and demonstrate their commitment to EHMSG.

The EHMSG 2020 meeting promises to be scientifically inspiring, providing the latest developments from the Helicobacter and Microbiota field.

I look forward to seeing you online!

Ceud Mìle Fàilte

Georgina Hold  
President of the EHMSG





## European Helicobacter & Microbiota Study Group EHMSG

### President of the EHMSG

Georgina Hold, Australia

### Members and International Scientific Committee

Leif P. Andersen, Denmark  
Lars Engstrand, Sweden  
Antonio Gasbarrini, Italy  
Javier P. Gisbert, Spain  
Josbert Keller, The Netherlands  
Marcis Leja, Latvia  
José C. Machado, Portugal  
Peter Malfertheiner, Germany  
Francis Mégraud, France  
Colm A. O'Morain, Ireland  
Mirjana Rajilic-Stovanovic, Serbia  
Ari P. Ristimäki, Finland  
Theodore Rokkas, Greece  
Annemieke Smet, Belgium  
Herbert Tilg, Austria

### Honorary Members

Franco Bazzoli, Italy  
James G. Fox, United States  
David Y. Graham, United States  
Ernst Kuipers, The Netherlands  
Adrian Lee, Australia  
Barry Marshall, Australia  
Guido N.J. Tytgat, The Netherlands

### Corresponding Fellows

Niyaz Ahmed, India  
Dmitry Bordin, Russia  
Luis G. Vaz Coelho, Brazil  
Jae Gyu Kim, Korea  
Varocha Mahachai, Thailand  
Yaron Niv, Israel  
Chung-Ying Wu, Taiwan  
Yoshio Yamaoka, Japan  
Weicheng You, China

### Emeritus Members

Anthony Axon, United Kingdom  
Michel A.L. Deltenre, Belgium  
Bram Flahou, Belgium  
Giovanni Gasbarrini, Italy  
Alexander M. Hirschl, Austria  
Pierre Michetti, Switzerland  
José M. Pajares Garcia, Spain  
Ashley B. Price, United Kingdom  
Mario G. Quina, Portugal (†)  
Erik A.J. Rauws, The Netherlands  
Pentti I. Sipponen, Finland  
Torkel M. Wadström, Sweden

### Organizing Office

#### Core Agency Scientific and Administrative Secretariat

Vienna Medical Academy  
Catherine Tomek  
Alser Strasse 4  
A-1090 Vienna, Austria  
Phone: +43 1 405 13 83 18  
Fax: +43 1 405 13 83 918  
Email: [workshop@ehmsg.org](mailto:workshop@ehmsg.org)

## Workshops of the EHMSG

Bordeaux (1988)  
Ulm (1989)  
Toledo (1990)  
Bologna (1991)  
Dublin (1992)  
Brussels (1993)  
Houston (1994)  
Edinburgh (1995)  
Copenhagen (1996)

Lisbon (1997)  
Budapest (1998)  
Helsinki (1999)  
Rome (2000)  
Strasbourg (2001)  
Athens (2002)  
Stockholm (2003)  
Vienna (2004)  
Copenhagen (2005)

Wroclaw (2006)  
Istanbul (2007)  
Riga (2008)  
Porto (2009)  
Rotterdam (2010)  
Dublin (2011)  
Ljubljana (2012)  
Madrid (2013)  
Rome (2014)

Nicosia (2015)  
Magdeburg (2016)  
Bordeaux (2017)  
Kaunas (2018)  
Innsbruck (2019)  
Virtual Event (2020)  
Belgrade (2021)  
Glasgow (2022)  
Antwerp (2023)

**SAVE THE DATE**

**XXXIV Workshop of the  
European Helicobacter and  
Microbiota Study Group**

[www.ehmsg.org](http://www.ehmsg.org)

**SEPTEMBER 16 - 18, 2021  
BELGRADE | SERBIA**





08.15 – 08.30

### Welcome and Introduction

Georgina Hold, Sydney, Australia

08.30 – 08.50

### I - Introductory Lecture

Moderator: Georgina Hold

#### A tribute to George Sachs: pH & Hp revisited, then and now

Richard Hunt, Hamilton, ON, Canada

08.50 – 09.50

### II - Gastric Epithelium Homeostasis in Health and Disease

Moderators: Georgina Hold, José Machado

08.50 – 09.10

#### Unexpected role of TLR5: Flagellin-independent but T4SS-dependent activation control *Helicobacter pylori* infections

Steffen Backert, Erlangen, Germany

09.10 – 09.30

#### Molecular mechanisms of *Helicobacter pylori* disruption of epithelial integrity

Ceu Figueiredo, Porto, Portugal

09.30 09.50

#### Gastric organoids as a tool to study *Helicobacter* infection

Francesco Boccellato, Oxford, UK

09.50 – 10.00

10 minutes break

10.00 – 12.30

### III - Symposium: *H. pylori* diagnostics & treatment - I

Moderators: Javier Gisbert, Colm O'Morain

10.00 – 10.20

#### “Test and Treat” strategy with UBT: a cost effective strategy for the management of *H. pylori* infection in UK

Mark Pritchard, Liverpool, UK

10.20 – 10.40

#### Rationale behind UBT *H. pylori* screening and eradication therapy to reduce the risk of Upper GI bleeding in patients with myocardial Infarction. Insights from the HELP-PILOT study

Magnus Bäck, Stockholm, Sweden

10.40 – 11.00

#### Acid suppression – how much is needed?

Takahisa Furuta, Hamamatsu, Japan

11.00 – 11.20

#### Renaissance reviewed - Bismuth still needed?

Peter Malfertheiner, Magdeburg, Germany

11.20 – 11.30

10 minutes break

10.00 – 12.30

### III - Symposium: *H. pylori* diagnostics & treatment - II

Moderators: Francis Mégraud, Peter Malfertheiner

11.30 – 11.50

#### Overcoming antibiotic resistance – the Korean experience

Ji Yong Ahn, Ulsan, Korea

11.50 – 12.10

#### Guidelines are good – adherence is better

Pali Hungin, Durham, UK

12.10 – 12.30

#### Management of *H. pylori* infection based on global/regional guidelines

Seung Joo Kang, Seoul, Korea

Live Talks

On-Demand

e-Posters

Scientific Information

Acknowledgements

General Information



- 12.30 – 12.35** **IV - Presentation of the Journal “Microbiota in Health and Disease”**  
Moderators: Francis Mégraud, Peter Malfertheiner  
Francesco Franceschi, Rome, Italy
- 12.35 – 12.45** **V - Awarding of the Marshall & Warren Medal to Hazel Mitchell, Australia**  
Moderator: Georgina Hold  
Hazel Mitchell, Sydney, Australia
- 12.45 – 14.40** **EHMSG Quiz**  
Josbert Keller, Leiden, The Netherlands
- Lunch Break**  
Visit the virtual exhibition spaces of our sponsors and view the On-Demand Talks & e-Posters
- 14.40 – 15.40** **VII - Gut Microbiota in Health and Disease**  
Moderators: Mirjana Rajilic-Stojanovic, Lars Engstrand
- 14.40 – 15.00** **Microbial Therapeutics: Are we there yet? Clinicians perspective**  
Tariq Iqbal, Birmingham, UK
- 15.00 – 15.20** **Using the microbiome to turn liquid diet into solid food. The CD-TREAT diet for treating Crohn’s disease**  
Richard Hansen, Glasgow, UK
- 15.20 – 15.40** **Microbial transplant – what are the challenges?**  
Josbert Keller, Leiden, The Netherlands
- 15.40 – 15.50** **10 minutes break**
- 15.50 – 16.50** **VIII - EHMSG Guidelines initiative in microbiota handling**  
Moderators: Annemieke Smet, Josbert Keller
- 15.50 – 16.10** **The challenge of microbiota testing**  
Antonio Gasbarrini, Rome, Italy
- 16.10 – 16.30** **Requirements for optimal testing**  
Mirjana Rajilic-Stojanovic, Belgrade, Serbia
- 16.30 – 16.50** **Clinical relevance of microbiota signature**  
Gianluca Ianaro, Rome, Italy
- 16.50 – 17.00** **10 minutes break**
- 17.00 – 19.00** **IX - Symposium: Gastric Cancer – Early detection and prevention 2020**  
Moderators: Marcis Leja, Theodore Rokkas
- 17.00 – 17.20** ***H. pylori* in the stomach – factors contributing to its dominance**  
Richard Peek, Nashville, TN, USA
- 17.20 – 17.40** **Current epidemiology and gastric cancer patterns**  
Constanza Camargo, Rockville, USA
- 17.40 – 18.00** **Population-based screening of gastric cancer**  
Jin-Young Park, Lyon, France



18.00 – 18.30

***H. pylori* screen-and-treat: Pro & Con - Talk**

18.00 – 18.15 **Con:** Anthony O'Connor, Dublin, Ireland

18.15 – 18.30 **Pro:** Jan Bornschein, Oxford, UK

18.30 – 19.00

**Preneoplastic conditions - Tandem Talk**

18.30 – 18.45 **is it time for molecular risk prediction?** Marnix Jansen, London, UK

18.45 – 19.00 **how good is endoscopy?** Alexander Link, Magdeburg, Germany

19.00 – 19.15

**X - Closing Session**

Moderators: Antonio Gasbarrini, Ari Ristimäki

19.00 – 19.10

**Poster Awards**

Ari Ristimäki, Helsinki, Finland

19.10 – 19.15

**Presentation of the EHMSG Workshop 2021 in Belgrade**

Mirjana Rajilic-Stojanovic, Belgrade, Serbia

Live Talks

On-Demand

e-Posters

Scientific Information

Acknowledgements

General Information



**ON-DEMAND TALKS****The Gut Microbiota – the latest branch of medicine**

Juozas Kupcinskas, Kaunas, Lithuania

**Harnessing the microbiome – Virome Potential**

Indrani Mukhopadhyaya, Aberdeen, UK

**Practical Considerations for understanding the Microbiome**

Lars Engstrand, Solna, Sweden

**Microbiome Analysis – Bioinformatics Perspective**

Chris Quince, Warwick, UK

**Birth and Early Life**

Omry Koren, Safed, Israel

**Microbes and Brain Function**

Daniel Wall, Glasgow, UK

**Atopic disease**

Reetta Satokari, Helsinki, Finland

**Cancer**

Patricia Lepage, Jouy en Josas, France

**The Microbiota in Obesity Associated Disease**

Marie Joossens, Gent, Belgium

**The Microbiota and Liver Disease**

Debbie Shawcross, London, UK

**PPI treatment and its impact on the GI microbiota – any clinical relevance?**

Christian Schulz, Munich, Germany

**Microbial manipulation in IBS**

Magdy El-Salhy, Bergen, Norway

**Microbial manipulation in IBD**

Patrizia Kump, Graz, Austria



## Electronic Poster Round 1: Diagnosis of Helicobacter infection

### EP1.01

“Test-and-Treat” strategy with urea breath test: a cost-effective approach for the management of *Helicobacter pylori*-related dyspepsia and the prevention of peptic ulcer in the United Kingdom-Results of the Hp-Breath initiative  
*David Pritchard, Liverpool, United Kingdom*

### EP1.02

Comparative estimation of results of the new selective rapid urease test and detection of *H. pylori* in stool: a pilot study  
*Natalia Baryshnikova, St-Petersburg, Russian Federation*

### EP1.03

Screening for *Helicobacter pylori* infection and Clarithromycin resistance using real-time polymerase chain reaction  
*Mila Kovacheva-Slavova, Sofia, Bulgaria*

### EP1.04

Accuracy of the *Helicobacter pylori* diagnostic tests in patients with peptic ulcer bleeding- The results of a network meta-analysis  
*Nóra Vörhendi, Pécs, Hungary*

### EP1.05

*Helicobacter pylori* screening in patients with acute myocardial infarction  
*Robin Hofmann, Stockholm, Sweden*

### EP1.06

Diagnosis of *Helicobacter pylori* infection in the elderly by immunochromatographic assay-based stool antigen test  
*Yingjie Han, Beijing, China*

### EP1.07

Implementation of the program of the Scientific Society of Gastroenterologists of Russia „Physicians without helicobacteriosis“ in Chita  
*Elena Luzina, Chita, Russian Federation*

### EP1.08

‘*Helicobacter pylori* and mast cells in the mucous membrane of the stomach’  
*Natalya Samodurova, Voronezh, Russian Federation*

### EP1.09

‘Immunomorphological aspects of evaluating the interaction of mast cells and *Helicobacter pylori* in the stomach mucous’  
*Natalya Samodurova, Voronezh, Russian Federation*

## Electronic Poster Round 2: Treatment of Helicobacter infection

### EP2.01

Quality assessment of meta-analyses: probiotics and eradication of *Helicobacter pylori* infection  
*György Buzás, Budapest, Hungary*

### EP2.02

Rifabutin triple therapy for first-line and rescue treatment of *Helicobacter pylori* infection: a systematic review and meta-analysis  
*Doron Boltin, Petah Tikva, Israel*

### EP2.03

European registry on *Helicobacter pylori* management (Hp-EuReg): first-line therapy in Israel  
*Doron Boltin, Petah Tikva, Israel*

### EP2.04

Eradication rate of *Helicobacter pylori* infection in Chinese duodenal ulcer patients treated with Vonoprazan 20 mg versus Lansoprazole 30mg with bismuth containing quadruple therapy  
*Jiangbin Wang, Changchun, China*

### EP2.05

*Helicobacter pylori* eradication first- and second-line regimens prescriptions and effectiveness in Lithuania: Analysis From the European Registry on *H. pylori* Management (Hp-EuReg)  
*Laimas Jonaitis, Kaunas, Lithuania*

**EP2.06**

*Helicobacter pylori* eradication treatment in Lithuania during 2013-2019: trend analysis of the European Registry on *H. pylori* management (Hp-EuReg)

*Paulius Jonaitis, Kaunas, Lithuania*

**EP2.07**

Difference in the *Helicobacter pylori* eradication rates according to the time of treatment start in patients with peptic ulcer bleeding

*Hak Kim, Seoul, Korea, Republic of*

**EP2.08**

Current trend in the *Helicobacter pylori* eradication rates of first-line sequential and concomitant therapies in Korea: A nationwide multicenter retrospective study over the 10 years

*Byung-Wook Kim, Incheon, Korea, Republic of*

**EP2.09**

Comparing efficacy of *Helicobacter pylori* eradication regimens: Bismuth containing quintet therapy vs. moxifloxacin based sequential therapy as first-line eradication regimen

*Yoo Jin Kim, Bundang, Korea, Republic of*

**EP2.10**

First-line *H. pylori* eradication therapy in Europe: Results from 24,882 cases of the European Registry on *H. pylori* Management (Hp-EuReg)

*Javier Gisbert, Madrid, Spain*

**EP2.11**

Room for improvement in the treatment of *Helicobacter pylori* infection: lessons from the European Registry on *H. pylori* Management (Hp-EuReg)

*Javier Gisbert, Madrid, Spain*

**EP2.12**

European Registry on *H. pylori* Management (Hp-EuReg): empirical first-line treatment use and effectiveness trends in Europe in the period 2013-2020

*Javier Gisbert, Madrid, Spain*

**EP2.13**

European Registry on *H. pylori* Management (Hp-EuReg): Analysis of empirical second-line treatments in Europe

*Javier Gisbert, Madrid, Spain*

**EP2.14**

A deadly hug: chitosan microspheres functionalized with MSI-78A antimicrobial peptide kill *Helicobacter pylori*

*Diana Fonseca, Universidade do Porto, Portugal*

**EP2.15**

Bismuth quadruple three-in-one single capsule: 3 or 4 times daily? Sub-analysis of the Spanish data of the European Registry on *H. pylori* Management (Hp-EuReg)

*Javier Gisbert, Madrid, Spain*

**EP2.16**

European Registry on *H. pylori* Management (Hp-EuReg): Experience with single capsule bismuth quadruple therapy in 3,439 patients

*Javier Gisbert, Madrid, Spain*

**EP2.17**

Safety of the treatment of *H. pylori* infection: experience from the European Registry on *H. pylori* Management (Hp-EuReg) on 22,000 patients.

*Javier Gisbert, Madrid, Spain*

**EP2.18**

Bismuth quadruple regimen with tetracycline or doxycycline versus Pylera® as third-line rescue therapy for *H. pylori* infection: A prospective multicenter analysis of the European Registry on *Helicobacter pylori* Management (Hp-EuReg)

*Javier Gisbert, Madrid, Spain*



**EP2.19**

European Registry on *H. pylori* Management (Hp-EuReg): Clinical phenotypes through machine learning of first-line treated patients in Spain during the period 2013-2018

*Javier Gisbert, Madrid, Spain*

**EP2.20**

Empirical versus susceptibility-guided treatment of *Helicobacter pylori* infection: a meta-analysis

*Javier Gisbert, Madrid, Spain*

**EP2.21**

Real-world comparative effects of three-in-one single capsule bismuth quadruple therapy vs. non-bismuth quadruple concomitant therapy: Interim analysis of the European Registry on *H. pylori* Management (Hp-EuReg)

*Ignasi Puig, Madrid, Spain*

**EP2.22**

Antibiotic resistance trends of *Helicobacter pylori* naïve patients in the period 2013-2019: analysis of the European Registry on *H. pylori* Management (Hp-Eu-Reg)

*Luis Bujanda, Madrid, Spain*

**EP2.23**

Tailored therapy based on clarithromycin resistance is effective for the first-line therapy of *Helicobacter pylori*

*Sang Gon Moon, Seoul, Korea, Republic of*

**EP2.24**

*Helicobacter pylori* antibiotic resistance: data from the European Registry on *H. pylori* Management (Hp-EuReg)

*Luis Bujanda, Madrid, Spain*

**EP2.25**

Impact of *Helicobacter pylori* clarithromycin resistance on the treatment effectiveness: data of the European Registry on *H. pylori* Management (Hp-EuReg)

*Luis Bujanda, Madrid, Spain*

**EP2.26**

Trends in the effectiveness of eradication therapy in Russia

*Dmitry Bordin, Moscow, Russian Federation*

**EP2.27**

The comparison of side effects and effectiveness of standard triple therapy with clarithromycin and alternative high-dose amoxicillin / bismuth therapy in eradication of *H. pylori*

*Alise Lielause, Riga, Latvia*

**EP2.28**

The effects of Eupatilin of NSAID-gastropathy associated with *H. pylori*

*Igor Skrypnyk, Poltava, Ukraine*

**EP2.29**

Excellent performance of 2-weeks tailored triple therapy in *H. pylori* infected children: Interim results of the new EuroPedHp Registry

*Thu Giang Le Thi, Munich, Germany*

**EP2.30**

Myricetin as a natural compound sensitizing *H. pylori* to antibiotics

*Paweł Krzyżek, Wrocław, Poland*

**EP2.31**

Counteracting *Helicobacter pylori* using drug-free nanostructured lipid carriers (NLC)

*Rute Chitas, Porto, Portugal*

**EP2.32**

Effectiveness of first-line *H. pylori* eradication therapy according to the daily statin-use: analysis of the European Registry on *H.pylori* Management (Hp-EuReg)

*Maria Caldas, Madrid, Spain*

**EP2.33**

Effectiveness of first-line *H. pylori* eradication treatments in Spain: results from the European Registry on *H. pylori* management

(Hp-EuReg)  
*Maria Caldas, Madrid, Spain*

**EP2.34**

Effectiveness of second-line *H. pylori* eradication treatments in Spain: results from the European Registry on *H. pylori* management (Hp-EuReg)  
*Maria Caldas, Madrid, Spain*

**EP2.35**

Population study on the prevalence and antimicrobial resistance of *Helicobacter pylori* in West Flanders - Belgium.  
*Alexander Vanden Bulcke, Leuven, Belgium*

**EP2.36**

European registry on *H. pylori* management (Hp-EuReg): analysis of 1,782 empirical rescue therapies on third and subsequent lines  
*Diego Burgos-Santamaría, Madrid, Spain*

**EP2.37**

Autoprotobiotics in treatment of *Helicobacter pylori* gastritis  
*Elena Ermolenko, Saint-Petersburg, Russian Federation*

**EP2.38**

Antibiotics susceptibility testing increases *Helicobacter pylori* eradication rates in dyspeptic patients from Egypt: a randomized controlled trial  
*Mohamed Alborai, Darrasah, Egypt*

**EP2.39**

Nifuratel in the eradication of *Helicobacter pylori* infection in adults: results of a randomized comparative clinical trial  
*Natalia Dekhnich, Smolensk, Russian Federation*

**EP2.40**

Toxic effects of bismuth on *Helicobacter pylori* associated with the intra-gastric acidity: a transmission electron microscopy study  
*Yi-Chia Lee, Taipei, Taiwan*

**EP2.41**

A real-life study assessing the efficacy of single capsule Bismuth quadruple therapy supplemented with probiotics for *H. pylori* eradication in patients naïve to treatment in a high clarithromycin resistance area  
*K. Priadko, Naples, Italy*

**EP2.42**

Modified bismuth quadruple therapy with low dose metronidazole as first-line therapy for *Helicobacter pylori* infection  
*Gyu Young Pih, Seoul, Korea, Republic of*

**EP2.43**

*Helicobacter pylori* resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community  
*Francis Mégraud, Bordeaux, France*

**EP2.44**

Antibiotic Resistance Breakers to counteract the multidrug-resistance in *Helicobacter pylori*  
*Silvia Di Lodovico, Chieti, Italy*

**EP2.45**

The effectiveness of various anti *Helicobacter* therapy regimens in Ukraine  
*Yana Nikiforova, Kharkiv, Ukraine*

**EP2.46**

Potential role of new Resveratrol derivatives for the management of drug resistant *Helicobacter pylori* infection  
*Mara Di Giulio, Chieti, Italy*

**EP2.47**

Evaluation of antimicrobial activity against *Helicobacter pylori* and phytochemical analysis of extracts from *Passiflora* and *Ilex* species  
*Johan Castañeda, Bogota, Colombia*



**EP2.48**

Empiric versus Clarithromycin-Resistance-Guided Therapy for *Helicobacter pylori* based on Polymerase Chain Reaction Results in Patients with Gastric Neoplasms or Gastric MALT Lymphoma: a Randomized Controlled Trial  
*Jue Lie Kim, Seoul, Korea, Republic of*

**EP2.49**

Antioxidant and anti-inflammatory properties of a grape seed extracts against *Helicobacter pylori* infection  
*Teresa Alarcón, Madrid, Spain*

**EP2.50**

Effects of temperature on the growth and metronidazole resistance in *Helicobacter pylori*  
*Meiliang Gong, Beijing, China*

**EP2.51**

Amoxicillin secretion by gastric mucosa in patients with atrophic and nonatrophic gastritis undergoing *H. pylori* eradication therapy  
*Anastasiya Sablina, Saint-Petersburg, Russian Federation*

**EP2.52**

The chimeric protein CTB-multiHp: immunological features and the ability to inhibit *Helicobacter pylori* activities.  
*Beatriz Meza, La Paz, Mexico*

## Electronic Poster Round 3: Gastric cancer

**EP3.01**

Application of gold nanoparticles and metal oxide sensors for non-invasive detection of gastric cancer  
*Linda Mezmale, Riga, Latvia*

**EP3.02**

Identification of volatile organic compounds emitted by gastric juice  
*Linda Mezmale, Riga, Latvia*

**EP3.03**

*Helicobacter pylori* CagA hijacks cortactin to control host cell migration via Vav2-mediated small GTPase Rac1 activation  
*Steffen Backert, Erlangen, Germany*

**EP3.04**

The repeat regions of *Helicobacter pylori* VirB10-ortholog CagY can bind and activate toll-like receptor 5  
*Steffen Backert, Erlangen, Germany*

**EP3.05**

Overexpression of toll-like receptor 5 in *H. pylori* infected patients with or without neoplasia  
*Steffen Backert, Erlangen, Germany*

**EP3.06**

*H. pylori* chronic gastritis: OLGa and OLGIM evaluation and serum biomarkers for risk assessment of gastric cancer development in Brazilian patients  
*Luiz Coelho, Belo Horizonte, Brazil*

**EP3.07**

Evaluation of the nonspecific immunity in patients with gastric cancer with *Helicobacter pylori* infection  
*Olga Smirnova, Krasnoyarsk, Russian Federation*

**EP3.08**

The role of non-specific monocytic phagocytes in the progression of gastric cancer associated with *Helicobacter pylori* infection  
*Olga Smirnova, Krasnoyarsk, Russian Federation*

**EP3.09**

Features of lipid peroxidation and antioxidant protection in gastric cancer associated with *Helicobacter pylori* infection  
*Olga Smirnova, Krasnoyarsk, Russian Federation*

**EP3.10**

Peculiarities of glutathione antioxidant protection functioning in gastric cancer associated with *Helicobacter pylori* infection  
*Olga Smirnova, Krasnoyarsk, Russian Federation*

**EP3.11**

Trends in gastric cancer in the Alaska Native population, 1988-2017  
*Leisha Nolen, Anchorage, United States*

**EP3.13**

Gastric cancer risk factors due to life style  
*Elizaveta Ageeva, Simferopol, Russian Federation*

**EP3.14**

Aberrant MUC13 expression as prognostic marker for gastric cancer  
*Baptiste Oosterlinck, Antwerp, Belgium*

**EP3.15**

Cost-effectiveness of *Helicobacter pylori* screening and eradication to prevent stomach cancer in Spain  
*Teresa Alarcón, Madrid, Spain*

**EP3.16**

In vitro profiling of volatile organic compounds released and consumed by CLS-145 and HGC-27 gastric cell lines  
*Linda Mezmale, Riga, Latvia*

**EP3.18**

Endoscopic biopsy sampling during gastroscopy - discrepancies across Europe  
*Jan Bornschein, Oxford, United Kingdom*

**EP3.19**

Impact of *Helicobacter pylori* infection and its virulence factor CagA on DNA damage repair machinery  
*Eleftherios Kontizas, Athens, Greece*

**EP3.20**

The role of lactate in gastric carcinogenesis  
*Karla Vinasco-Pacheco, Sydney, Australia*

**EP3.21**

ER stress and inflammation via autophagy influence *Helicobacter pylori*-related gastric cancer  
*Isidora Simovic, Sydney, Australia*

**EP3.22**

Leukaemia Inhibitory Factor signalling for targeting cancer stem cells in gastric adenocarcinoma  
*Lornella Seeneevassen, Bordeaux, France*

**EP3.23**

Cell-free DNA somatic alterations in plasma of gastric cancer patients: mutational spectra, association with tumor size and survival  
*Greta Streleckiene, Kaunas, Lithuania*

**EP3.24**

Induction of precancerous phenotype of normal gastric epithelial cells after their long-term incubation with supernatant from *Helicobacter pylori*-infected cancer-associated fibroblasts in vitro. Involvement of transforming growth factor beta and its receptor  
*Tomasz Brzozowski, Cracow, Poland*

**EP3.25**

Microbial abundance of *H. pylori* assessed by high-throughput sequencing and prognosis of gastric cancer patients  
*Alexander Link, Magdeburg, Germany*

**EP3.26**

*Helicobacter pylori* and Epstein-Barr virus co-infection in Greek patients with gastric malignancies  
*Beatriz Martinez-Gonzalez, Athens, Greece*

**EP3.27**

Increasing trend of gastroesophageal junction in the primary site of endoscopic resected gastric cancers  
*Younghee Choe, Seoul, Korea, Republic of*



## response

### EP4.01

Important role of integrin receptors in controlling the AGS cell elongation/hummingbird phenotype by *Helicobacter pylori* CagA  
Steffen Backert, Erlangen, Germany

### EP4.02

The actin-binding protein cortactin is required for efficient AGS cell elongation by *H. pylori* CagA, but not for vacuolization and apoptosis by VacA  
Steffen Backert, Erlangen, Germany

### EP4.03

Type IV secretion of *Helicobacter pylori* CagA and ADP-heptose into oral epithelial cell lines  
Steffen Backert, Erlangen, Germany

### EP4.04

The role of pro-inflammatory and anti-inflammatory cytokines in the development of chronic atrophic gastritis with *Helicobacter pylori* infection  
Olga Smirnova, Krasnoyarsk, Russian Federation

### EP4.05

Immunoglobulins in chronic gastritis and chronic atrophic gastritis with *H. pylori* infection  
Olga Smirnova, Krasnoyarsk, Russian Federation

### EP4.06

Features of the functioning of monocytes in chronic gastritis associated with *Helicobacter pylori*-infection  
Olga Smirnova, Krasnoyarsk, Russian Federation

### EP4.07

Role of monocytes during chronic atrophic gastritis associated with *Helicobacter pylori* infection  
Olga Smirnova, Krasnoyarsk, Russian Federation

### EP4.08

Features of lipid peroxidation and antioxidant protection in chronic atrophic gastritis associated with *Helicobacter pylori* infection  
Olga Smirnova, Krasnoyarsk, Russian Federation

### EP4.09

The role of the glutathione part of antioxidant protection in the development of atrophy in chronic gastritis associated with *Helicobacter pylori* infection  
Olga Smirnova, Krasnoyarsk, Russian Federation

### EP4.10

Indicators of proliferation and apoptosis of gastric epithelial cells in the indigenous inhabitants of the Republic of Tyva with *Helicobacter pylori*-positive duodenal ulcer  
Vladislav Tsukanov, Krasnoyarsk, Russian Federation

### EP4.11

Immunophenotype of cell infiltrate of the gastric mucosa lamina propria in indigenous inhabitants of Khakassia with *Helicobacter pylori*-positive duodenal ulcer  
Vladislav Tsukanov, Krasnoyarsk, Russian Federation

### EP4.12

Upregulation of intercellular cell adhesion molecule-1 in endothelial cells exposed to *Helicobacter pylori* outer membrane vesicles  
Jung Mogg Kim, Seoul, Korea, Republic of

### EP4.13

*Helicobacter pylori* infection affects nitric oxide system in patients with chronic antral gastritis and diabetes mellitus type 2  
Igor Skrypnyk, Poltava, Ukraine

### EP4.14

Active forms of oxygen in monocyte culture under high dissemination with *Helicobacter pylori*  
Irina Litvinova, Krasnoyarsk, Russian Federation

### EP4.15

*Helicobacter pylori* alters expression of Notch pathway components in gastric epithelial cells and macrophages in a cell type specific manner.

Rebecca FitzGerald, Dublin, Ireland

#### EP4.16

Presence of Matrix Metalloproteinase-9-positive Neutrophil Extracellular Traps (NETs) in gastric biopsies of *H. pylori* infected patients

Elissavet Michailou, Athens, Greece

#### EP4.17

Virulence gene *cagA* of *Helicobacter pylori* and severe esogastroduodenal diseases: is there a relationship?

Mônica Barbosa, Goiânia, Brazil

#### EP4.18

Clinical Treatment Outcomes and Prognosis of Gastric MALToma : A Single Center Experience

Won Shik Kim, Seoul, Korea, Republic of

#### EP4.19

*Helicobacter pylori dupA* virulence gene: risk factor or protector of gastropathies?

Mônica Barbosa, Goiânia, Brazil

#### EP4.20

Contribution of *Helicobacter pylori* to foam cell formation in experimental atherosclerosis

Agnieszka Krupa, Lodz, Poland

#### EP4.21

Modulation of Nrf2-mediated antioxidant response after infection with *Helicobacter pylori* may contribute to gastric cancer

Océane Martin, Bordeaux, France

#### EP4.22

Modulation of *Helicobacter pylori* adhesion to gastric epithelial cells by BCGOnko vaccine mycobacteria

Weronika Gonciarz, Lodz, Poland

#### EP4.23

Induction of autoantibodies in response to infection with CagA-positive *Helicobacter pylori*

Weronika Gonciarz, Lodz, Poland

## Electronic Poster Round 5: Epidemiology

#### EP5.01

Prevalence and genetic features of drug resistant *Helicobacter pylori* strains from Zhengzhou

Chuan Liu, Zhengzhou, China

#### EP5.02

Prevalence of *Helicobacter pylori* infection in north-eastern Romania- data from a tertiary care center

Elena Popovici, Iasi, Romania

#### EP5.03

Changes in the prevalence of *Helicobacter pylori* over last 25 years among Lithuanian medical students

Laimas Jonaitis, Kaunas, Lithuania

#### EP5.04

Evaluation of dyspeptic symptoms in *Helicobacter pylori*-positive and negative students of Lithuanian University of Health Sciences

Laimas Jonaitis, Kaunas, Lithuania

#### EP5.05

The prevalence of CagA *Helicobacter pylori* in children of the Mongoloid population of Siberia

Tamara Polivanova, Krasnoyarsk, Russian Federation

#### EP5.06

The influence of parental education on the prevalence of *Helicobacter pylori* in rural children

Tamara Polivanova, Krasnoyarsk, Russian Federation

#### EP5.07



Trends in the prevalence of *Helicobacter pylori* in Russia  
*Dmitry Bordin, Moscow, Russian Federation*

**EP5.08**

Time trends in acute upper gastrointestinal bleeding in Serbian adult population  
*Vladimir Milivojevic, Belgrade, Serbia*

**EP5.09**

Relationship of *Helicobacter pylori* infection to lifestyle, sociodemographic and economic profile in dyspeptic patients  
*Mônica Barbosa, Goiânia, Brazil*

**EP5.10**

Retrospective analysis of the *H. pylori* eradication rates in Crimean population.  
*Valeriy Kryvy, Simferopol, Russian Federation*

**EP5.11**

*Helicobacter pylori* reinfection rates in Crimean population: follow-up study  
*Valeriy Kryvy, Simferopol, Russian Federation*

## Electronic Poster Round 6: Microbiology and genomics of *Helicobacter*

**EP6.01**

Changes in the fluoroquinolone resistance of *Helicobacter pylori* over a 14-year period and discovery of a novel mutation in DNA gyrase: a single center study in Korea  
*Jae Kim, Seoul, Korea, Republic of*

**EP6.02**

Clarithromycin resistance of *Helicobacter pylori* strains isolated in St. Petersburg, Russia  
*Alena Svarval, Saint Petersburg, Russian Federation*

**EP6.03**

The genomic polymorphism of clinical strains of *H. pylori* isolated in St. Petersburg, Russia.  
*Alena Svarval, Saint Petersburg, Russian Federation*

**EP6.04**

*Helicobacter pylori* resistance, treatment outcome and point mutation analysis based on molecular testing in Serbian adult population  
*Vladimir Milivojevic, Belgrade, Serbia*

**EP6.05**

Clarithromycin resistance is more common among less virulent *Helicobacter pylori* strains - Data from an Irish centre.  
*Rebecca Fitzgerald, Dublin, Ireland*

**EP6.06**

Pathway of focal adhesion and its relevant circRNAs and lncRNAs are involved with perianal Crohn's disease.  
*Shi-xue Dai, Guangzhou, China*

**EP6.07**

Comparison in vitro of activity of various macrolides against *Helicobacter pylori*  
*Natalia Dekhnich, Smolensk, Russian Federation*

**EP6.08**

East-Asian *Helicobacter pylori* strains synthesize heptan-deficient lipopolysaccharide  
*Hong Li, Chengdu, China*

**EP6.09**

The role of two PDZ domains in HtrA from *Helicobacter pylori* in the protein quality control system  
*Urszula Zarzecka, Gdansk, Poland*

**EP6.10**

New *Helicobacter pylori* prophage phylogenetic population from Colombian strains  
*Angela Muñoz, Bogotá, Colombia*

**EP6.11**

Frequency of *Helicobacter pylori* *cagA*, *dupA* and *vacA* genotypes and their association with severity of gastric pathologies in clinical patients in midwestern Brazil  
*Mônica Barbosa, Goiânia, Brazil*

**EP6.12**

Comparative genomic analysis of novel *Helicobacter pylori* strains isolated from domestic cats with gastritis reveals unique genetic profile that may contribute to colonization and pathogenicity in feline hosts  
*Anthony Mannion, Cambridge, United States*

**EP6.13**

Current worldwide population structure of *Helicobacter pylori*  
*Roberto Torres, Shanghai, China*

**EP6.14**

Muller's ratchet-like effect in *Helicobacter pylori*, a highly recombining bacterial species.  
*Elise Tourrette, Shanghai, China*

**EP6.15**

Characterization of *Helicobacter pylori* Infection in the upper gastrointestinal tract of Twins.  
*Alexander Link, Magdeburg, Germany*

## Electronic Poster Round 7: *Helicobacter* and extragastroduodenal disease

**EP7.01**

A potential association between *Helicobacter pylori* infection and metabolic syndrome-related nonalcoholic fatty liver disease severity  
*Jannis Kountouras, Thessaloniki, Macedonia, Greece*

**EP7.02**

Impact of *Helicobacter pylori* eradication on the risk of incident nonalcoholic fatty liver disease  
*Hyuk Lee, Seoul, Korea, Republic of*

**EP7.03**

Cohort study of *Helicobacter pylori* infection and the risk of Incident osteoporosis in women  
*Hyuk Lee, Seoul, Korea, Republic of*

**EP7.04**

The prevalence of *Helicobacter pylori* and the structure of the gastric mucosa in elderly patients with GERD  
*Vladislav Tsukanov, Krasnoyarsk, Russian Federation*

**EP7.05**

Clinical implication of *Helicobacter pylori* infection for eosinophilic esophagitis : A single center experience  
*Eun Ji Lee, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Republic of*

**EP7.06**

The features of *Helicobacter pylori* infection and gastrointestinal manifestations of allergy in children of Eastern Siberia  
*Anna Barilo, Krasnoyarsk, Russian Federation*

**EP7.07**

*H. pylori* prevalence in individuals with allergic disease in the Latvian population  
*Jelizaveta Aleksejeva, Riga, Latvia*

**EP7.08**

*Helicobacter pylori* outer membrane vesicles induce astrocyte reactivity  
*Esteban Palacios, Santiago, Chile*

**EP7.09**

Strain specific pathological changes in the liver of mice infected with *Helicobacter pylori* (*H. pylori*).  
*Sadia Khalid, Tallinn, Estonia*

**EP7.10**



*Helicobacter pylori*-induced inflammatory response mediates invadosome formation and emergence of hybrid epithelial mesenchymal phenotype in infected hepatocytes  
*Olga Smirnova, Tallinn, Estonia*

**EP7.11**

Role of Helicobacters in Idiopathic Parkinsonism: a systematic review  
*Rosalind Tucker, London, United Kingdom*

**EP7.12**

*H. pylori* Associated to Irritable Bowel Syndrome (IBS)  
*Adriana Barrios, Quetzaltenango, Guatemala*

## Electronic Poster Round 8: Paediatric conditions

**EP8.01**

The peculiarities of stomach mucosa in *Helicobacter pylori* schoolchildren  
*Tamara Polivanova, Krasnoyarsk, Russian Federation*

**EP8.02**

Cytokines in *Helicobacter pylori*-associated gastritis in children with a family predisposition to gastric pathology  
*Tamara Polivanova, Krasnoyarsk, Russian Federation*

**EP8.03**

Cytokeratins CK20, CK7 in assessing the severity of lesions of the gastric mucosa in schoolchildren with *Helicobacter pylori* associated gastritis  
*Tamara Polivanova, Krasnoyarsk, Russian Federation*

**EP8.04**

Levels of IL-2, IL-4 with erosive and ulcerative lesions of the gastroduodenal zone associated with *Helicobacter pylori* in schoolchildren with pathology of the digestive tract in parents  
*Tamara Polivanova, Krasnoyarsk, Russian Federation*

**EP8.05**

Is CDX2 in children an immunohistochemical marker for the adverse course of gastritis?  
*Tamara Polivanova, Krasnoyarsk, Russian Federation*

**EP8.06**

The relationship of blood leptin with *Helicobacter pylori* in children  
*Tamara Polivanova, Krasnoyarsk, Russian Federation*

**EP8.07**

Chronic *Helicobacter pylori* infection in Siberian adolescents with gastroesophageal reflux disease (GERD)  
*Sergey Tereshchenko, Krasnoyarsk, Russian Federation*

**EP8.08**

Efficacy of standard triple therapy in the eradication of *Helicobacter pylori* in Siberian children: a single centre experience of treatment outcomes  
*Sergey Tereshchenko, Krasnoyarsk, Russian Federation*

**EP8.09**

Effect of *Helicobacter pylori* on the formation of erosive-ulcerative lesions of the gastroduodenal zone, GERD and their associative relationship  
*Tamara Polivanova, Krasnoyarsk, Russian Federation*

**EP8.10**

Application of liquid probiotic concentrate for gastroduodenitis of Helicobacter etiology in children  
*Olga Obukhova, Novosibirsk, Russian Federation*

**EP8.11**

*H. pylori* infection in symptomatic Mexican children  
*Omaha Celestino-Perez, Mexico City, Mexico*

## Electronic Poster Round 9: Upper GI microbiota in health and disease

**EP9.01**

Treatment of non-erosive reflux disease and change of esophageal microbiome: A prospective multicenter study  
*Sang Kil Lee, Seoul, Korea, Republic of*

**EP9.02**

Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: A prospective multicenter study  
*Chan Hyuk Park, Guri, Korea, Republic of*

**EP9.03**

*Helicobacter pylori* and the possible probiotic *Lactobacillus salivarius* co-exist in Estonian gastric biopsy sample  
*Kaisa Roots, Tallinn, Estonia*

## Electronic Poster Round 10: Gut microbiota and non-intestinal disease

**EP10.01**

Effect of fecal microbiota transplantation on clearance of carbapenem resistant enterobacteraceae  
*yong woon Shin, Incheon, Korea, Republic of*

**EP10.02**

Gut microbiota depending on the atopic dermatitis severity in children in Eastern Siberia  
*Anna Barilo, Krasnoyarsk, Russian Federation*

**EP10.03**

Watercress and the gut  
*Kyle Stewart, Newton Abbot, Devon, United Kingdom*

## Electronic Poster Round 11: Microbiota and intestinal disease

**EP11.01**

Trimebutine maleate as a multidimensional-antibacterial agent against functional dyspepsia: a prospective multicenter randomized, double-blind controlled trial  
*Jannis Kountouras, Thessaloniki, Greece*

**EP11.02**

Gut microbiota disorders in patients with inflammatory bowel diseases  
*Natalia Baryshnikova, St-Petersburg, Russian Federation*

**EP11.03**

Comparison of glucose and lactulose breath test results for detecting small intestinal bacterial overgrowth  
*Arta Denina, Riga, Latvia*

**EP11.04**

The prevalence of *Helicobacter pylori* and protozoan invasions and the impact on the performance of enzymic digestions  
*Guzel Isaeva, Kazan, Russian Federation*

**EP11.05**

Fecal Microbiota Transplantation as treatment for recurrent *Clostridioides difficile* infection in patients with Inflammatory Bowel Disease: Experiences of the Netherlands Donor Feces Bank  
*Emilie van Lingen, Leiden, Netherlands*

**EP11.06**

A considerable rate of COVID-19 GI symptoms is associated with antimicrobial therapy: findings from a large western prospective cohort  
*Serena Porcari, Rome, Italy*

## Electronic Poster Round 12: Microbiota and cancer



## EP12.01

The clinical outcomes of treatment for low grade gastric mucosa associated lymphoid tissue lymphoma unresponsive to *Helicobacter pylori* eradication  
*Sunah Suk, Seoul, Korea, Republic of*

## Electronic Poster Round 13: Gut microbiota manipulation

### EP13.01

Initial experience of the first Brazilian stool bank with fecal microbiota transplantation for recurrent *Clostridioides difficile* infection  
*Luiz Gonzaga Coelho, Belo Horizonte, Brazil*

### EP13.02

Impact of high fat diets with different content of unsaturated fatty acids on hydrogen gas generation by the gut microbiota in rats  
*Anastasiia Ivanova, Moscow, Russian Federation*

## Electronic Poster Round 14: Microbiota detection and analyses

### EP14.01

Circulating blood microbiome signatures in patients with liver cirrhosis: association between clinical parameters, circulating taxa and inflammatory cytokines  
*Rolandas Gedgaudas, Kaunas, Lithuania*

### EP14.02

Laboratory assessment of a device prototype for Methane and Hydrogen breath testing  
*Elena Kolomina, St. Petersburg,, Russian Federation*

### EP14.03

Multiparameter flow cytometric enumeration of the commercial probiotic products  
*Katarzyna Sielatycka, Szczecin, Poland*

### EP14.04

In-depth comparison of different platforms for high throughput sequencing microbiome analyses of gastric mucosa  
*Alexander Link, Magdeburg, Germany*



## LIVE SESSIONS

### Session Structure for Live Presentations

All sessions include pre-recordings as well as a live component. We want to make sure to retain as much human interaction as possible.

Prior to the session, all lectures are recorded and uploaded to our system. They need to be of an exact length (as indicated in your information mailing) to ensure smooth development of the session.

At the scheduled timeslot of the session, the chairperson of the session will open the session and introduce the speakers.

Then the recording of the first lecture will be played. At all times there is a live-chat available, where all participants can contribute to the session or ask questions which will be monitored by the moderator.

After each lecture, there is some time reserved for a discussion with the chairperson. Lecturers and chairpersons therefore need to be online at the scheduled timeslot. They will discuss questions from the audience or further details of the session. This is the same procedure for all lectures.

### Commercial Disclosure information

Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

### Speaking Time

The chairpersons of live sessions will be strict in allowing no more than the time allotted to discussions following the pre-recorded presentations.

Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion.

## ON-DEMAND TALKS & e-POSTER PRESENTATIONS

On-Demand Talks and e-Poster presentations can be viewed by participants "on-demand", which means that individual presentations do not have dedicated times at which they can be viewed – they can be viewed at any time. Authors of e-Poster presentations can be contacted via a messaging system on the conference platform as of September 12, 2020.


## AVAILABILITY OF PRESENTATIONS DURING AND AFTER THE CONFERENCE

All on-demand and e-poster presentations will be available (for registered participants only) on the virtual platform on the day of the conference and remain there for review until one month after the conference.

All live presentations will be moved to the on-demand section after September 12, 2020 and remain available there for review (for registered participants only) until one month after the conference.

**Microbiota in Health and Disease, the official journal of the European Helicobacter and Microbiota Study Group – EHMSG**, is focused on all issues related to the role of microbiota in maintaining health or promoting diseases, not only confined to the GI tract.

Its scope ranges from publishing papers on novelties in basic science, translational research, clinical trials and new therapeutic options, in order to supply international researchers with a valuable platform of discussion of challenges and opportunities in the field of microbiota.



You are kindly invited to submit your valuable paper completely

**FREE OF CHARGE**



## Acknowledgements

The organisers gratefully acknowledge the support of the following institutions and companies:





*In alphabetical order.*

## Breaks and Lunch Break

During the session breaks we invite you to visit our sponsors virtual exhibition spaces as well as the on-demand and e-Poster presentations.

## Cancellations and Refunds

Registration fees may be refunded if written cancellation has been received as follows:

- until August 16, 2020: full refund
- between August 17 – September 8, 2020: 50% refund
- from September 9, 2020: no refund

The cancellation will not be effective until a written acknowledgement from the Congress Office is received. In the case of over-payment or double payment, refund requests must be made in writing and sent to the Congress Office by e-mail. No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers or any other incidents during the conference, which are beyond the control of the conference organisers.

No exceptions to the refund policy can be made, including health or family issues. By registering to EHMSG 2020, participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Refunds will be made after September 12, 2020

## Certificate of Attendance

Confirmations of attendance will be issued to all registered participants and sent via e-mail.

## CME Credits

The “XXXIII<sup>d</sup> International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer” taking place virtually was granted a total of **7 European CME credits** (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

## Functionality of the virtual platform

The conference organiser’s subcontractors provide a high level of availability of their network, cannot however give any guarantee that their network will operate without any interruptions or malfunctions.

No assurances or guarantees can be given about the availability, quality, operation or support services for data traffic, on the networks, or lines of the participant’s Internet provider.

The conference organiser is not liable if the provision of the services is interrupted, partially restricted, or impossible as a result of force majeure. Force majeure is for example considered natural phenomena of significant intensity (avalanches, floods, etc.), conflicts, terrorism, strikes, unexpected official restrictions, power cuts, computer viruses, worms, Trojan horses etc.

## Language

The official language of the workshop is English (no simultaneous translation).

## Liability

In registering for the EHMSG 2020 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. The organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

## Opening hours of the Virtual Conference and Virtual Exhibition on September 12, 2020

08.15 – 19.15 hrs **CEST**

All Live Talks, On-Demand Talks and e-Poster presentations will be available in the On-Demand Section after the conference as of September 13, 2020 until October 12, 2020.



## Presentations

All presenters are requested to upload their pre-recorded presentations on the virtual platform until September 3, 2020. **Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide.** A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts. If you have nothing to disclose, please state “I have no commercial disclosure” instead of the table.

## Registration Details

### Registration Fees (one fee applies for all participants)

Regular Participants	EUR 100.–
----------------------	-----------

**Payment of Registration fees** may be made either by Credit Card (Diners Club, Mastercard and Visa) at any time, or by bank transfer until September 1, 2020

### What is covered by the registration fee?

- Access through the virtual platform to all scientific sessions
- Access through the virtual platform to all recorded sessions until October 12, 2020
- Access through the virtual platform to all company exhibition spaces

## Twitter

The European Helicobacter and Microbiota Study Group is present on Twitter @ehmsg. We invite you to follow us on Twitter, engage and discuss with your colleagues.

**Detect and confirm** eradication of an  
**active *H. pylori*** infection in just minutes

**curian**<sup>®</sup>  
HpSA<sup>®</sup>



## Compact, sample-to-result GI assay platform



**Simple** sample prep



**Easy**, standardized workflow - less than 1 minute hands-on time



**Flexible** testing options - batch or load-and-go option



Fluorescent technology **improves performance, removes subjectivity**



Visit Curian<sup>®</sup> HpSA<sup>®</sup> virtually  
[www.meridianbioscience.com/meetcurian](http://www.meridianbioscience.com/meetcurian)



Let's get social!



**meridian** BIOSCIENCE<sup>®</sup>  
LIFE DISCOVERED. LIFE DIAGNOSED.

# New Instruments Generations in Breath Test Analysis

TIME FOR CHANGE



**IR-FORCE 200 Android**



**IR-FORCE 200 Fancy**



**IR-FORCE 300 Plus**

# Helicobacter Test INFAl®

One of the most used  $^{13}\text{C}$ -urea breath tests for the diagnosis of Hp-infections worldwide



- New line of INFAl packaging and serialization according the EU's Falsified Medicines Directive
- More than 6.8 million Helicobacter Test INFAl performed worldwide
- Registered in more than 40 countries worldwide
- First approved Hp test for children from the ages of 3 to 11
- Modified Hp test for patients taking PPIs (REFEX)
- Cost-effective CliniPac Basic for hospital and GPs use



INFAl GmbH  
Riehler Str. 36  
50668 Cologne  
Germany

Phone: +49 221 880 44-3  
Fax: +49 221 880 44-55  
Email: [mail@infai.de](mailto:mail@infai.de), [info@infai.co.uk](mailto:info@infai.co.uk)  
Web: [www.infai.de](http://www.infai.de), [www.infai.co.uk](http://www.infai.co.uk)